1. 2022-RA-722-ESGO Phase 2 study assessing the efficacy of adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to chemotherapies in subjects with platinum resistant ovarian carcinoma. (20th October 2022) Authors: Miller, David Scott; Carlson, Matthew; Lea, Jayanthi; Li, Zhe; Gan, May; Chen, Judy; Garcia, Agustin; Schlumbrecht, Matthew; Pearson, Matt; Huang, Marilyn Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗